Background: Fanconi anemia is a rare autosomal recessive disorder of genetic instability. It is both molecularly and clinically, a heterogeneous disorder. Its incidence is 1 in 129,000 births and relatively high in some ethnic groups. Sixteen genes have been identified among them mutations in FANCG gene are most common after FANCA and FANCC gene mutations.
Objective: To study mutations in exon 3 and 4 of FANCG gene in Pakistani population.
Methods: Thirty five patients with positive Diepoxybutane test were included in the study. DNA was extracted and amplified for exons 3 and 4. Thereafter Sequencing was done and analyzed for the presence of mutations.
Results: No mutation was detected in exon 3 whereas a carrier of known mutation c.307+1 G>T was found in exon 4 of the FANCG gene.
Conclusion: Absence of any mutation in exon 3 and only one heterozygous mutation in exon 4 of FANCG gene points to a different spectrum of FA gene pool in Pakistan that needs extensive research in this area.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5507/bp.2017.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic significance of mutation type and chromosome fragility in Fanconi anemia.
Am J Hematol
February 2025
Joint Research Unit on Genomic Medicine, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain.
Article Synopsis
- Fanconi anemia (FA) is a rare genetic disorder marked by varying symptoms and significant chromosome fragility, leading to severe health issues like cancer and bone marrow failure.
- The Spanish Registry of Patients with FA gathered data from 227 patients over 30 years, revealing an 86% cumulative cancer incidence by age 50, with outcomes differing based on chromosome fragility and specific gene mutations.
- Findings suggest that patients with mutations allowing some protein function (genetic hypomorphism) tend to have better health outcomes, indicating potential for new therapies that could enhance mutant FA protein function to improve patient prognosis.
Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors.
Front Med (Lausanne)
October 2024
University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, United States.
Article Synopsis
- Recent research has expanded the concept of "FA signaling" to include over 30 proteins involved in DNA Damage Response (DDR), making it the largest cellular defense network against DNA damage.
- Different human cancers display unique mutational profiles related to DDR/FA signaling, with ATM and BRCA2 being major players across many cancer types, while genes like FANCT predominate in breast and liver cancers.
- Understanding these mutation patterns is crucial, as they greatly influence patient survival and treatment outcomes, potentially guiding more effective therapeutic strategies for various cancers.
Clinicopathological and molecular genetic insights into EBV-positive inflammatory follicular dendritic cell sarcoma.
Hum Pathol
November 2024
Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, Fujian, China. Electronic address:
Article Synopsis
- - This study focused on analyzing 12 cases of Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV + IFDCS) to understand its clinical and pathological features, which are not fully described.
- - Patients ranged in age from 21 to 84 years, with a predominance of females, and all were alive at the last follow-up despite some experiencing recurrence or metastasis; various subtypes were identified within the cases.
- - The study revealed significant differences in marker expressions between EBV + IFDCS and traditional follicular dendritic cell sarcoma (FDCS), along with unique genetic mutations and variations that were observed, contributing to a better understanding of this rare condition
Genomic alterations in two patients with esophageal carcinosarcoma identified by whole genome sequencing: a case report.
Surg Case Rep
August 2024
Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka, 411-8777, Japan.
Background: Esophageal carcinosarcoma (ECS) is a relatively rare malignancy, accounting for < 1% of all esophageal cancers. Its etiopathogenesis remains unknown. This study analyzed the genomic abnormalities in sarcomatous tumors from two patients undergoing subtotal esophagectomy using whole genome sequencing to elucidate the key characteristics of ECS.
View Article and Find Full Text PDFA comprehensive study evaluating germline FANCG variants in predisposition to breast and ovarian cancer.
Cancer Med
August 2024
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Article Synopsis
- Monoallelic germline pathogenic variants in certain Fanconi anemia genes are known to increase breast and ovarian cancer risk, but the effects of variants in FANCG/XRCC9 remain unclear.
- Researchers found that the frequency of truncating variants in FANCG did not significantly differ between breast cancer, ovarian cancer patients, and controls.
- The study concludes that heterozygous germline FANCG variants are unlikely to play a role in developing breast or ovarian cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!